Technical Analysis for EARS - Auris Medical Holding AG
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical EARS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 17 | Fell Below 20 DMA | Bearish | -2.69% |
| Jan 17 | Wide Bands | Range Expansion | -2.69% |
| Jan 16 | 20 DMA Support | Bullish | -7.82% |
| Jan 16 | Wide Bands | Range Expansion | -7.82% |
| Jan 15 | Shooting Star Candlestick | Bearish | -13.70% |
| Jan 15 | Pocket Pivot | Bullish Swing Setup | -13.70% |
| Jan 15 | Volume Surge | Other | -13.70% |
| Jan 15 | Wide Bands | Range Expansion | -13.70% |
| Jan 15 | Upper Bollinger Band Touch | Strength | -13.70% |
| Jan 14 | 20 DMA Support | Bullish | -5.89% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-15
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its lead product candidate includes AM-101, which is in Phase III clinical trials for treating acute inner ear tinnitus. The company is also developing AM-111 for the treatment of acute sensorineural hearing loss, as well as for Meniere diseases; and other development programs comprising AM-102 and AM-123 that are in preclinical studies. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, and drug delivery devices and formulations for the treatment of inner ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more EARS news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 5.3 |
| 52 Week Low | 0.23 |
| Average Volume | 2,055,106 |
| 200-Day Moving Average | 0.7388 |
| 50-Day Moving Average | 0.528 |
| 20-Day Moving Average | 0.4305 |
| 10-Day Moving Average | 0.4504 |
| Average True Range | 0.0644 |
| ADX | 13.04 |
| +DI | 25.3859 |
| -DI | 20.7218 |
| Chandelier Exit (Long, 3 ATRs ) | 0.3468 |
| Chandelier Exit (Short, 3 ATRs ) | 0.4982 |
| Upper Bollinger Band | 0.5211 |
| Lower Bollinger Band | 0.3399 |
| Percent B (%b) | 0.42 |
| BandWidth | 42.090592 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.0258 |
| MACD Histogram | 0.0058 |
| Fundamentals | Value |
|---|---|
| Market Cap | 18.48 Million |
| Num Shares | 44.3 Million |
| EPS | -0.75 |
| Price-to-Earnings (P/E) Ratio | -0.56 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 6.14 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.47 | ||||
| Resistance 3 (R3) | 0.47 | 0.46 | 0.46 | ||
| Resistance 2 (R2) | 0.46 | 0.45 | 0.46 | 0.46 | |
| Resistance 1 (R1) | 0.44 | 0.44 | 0.43 | 0.43 | 0.46 |
| Pivot Point | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 |
| Support 1 (S1) | 0.40 | 0.41 | 0.40 | 0.40 | 0.38 |
| Support 2 (S2) | 0.39 | 0.40 | 0.39 | 0.38 | |
| Support 3 (S3) | 0.37 | 0.39 | 0.37 | ||
| Support 4 (S4) | 0.36 |
